Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) in patients without cardiac-dose limiting toxicity (cDLT). The graphs show trend in left ventricular ejection fraction (a) and global longitudinal strain (b, scale reversed for ease of interpretation) in patients without cDLT (n = 47) in the study. Bars represent percent of patients on trastuzumab at each time point. Table accompanying each graph shows the number of patients who demonstrated normalized LVEF (≥54%) or normalized GLS (≤−17% or to baseline level) at each time point. P-values represent the comparison of LVEF or GLS with baseline values at selected time points.